US20110027832A1 - Use of taq polymerase mutant enzymes for nucleic acid amplification in the presence of pcr inhibitors - Google Patents

Use of taq polymerase mutant enzymes for nucleic acid amplification in the presence of pcr inhibitors Download PDF

Info

Publication number
US20110027832A1
US20110027832A1 US12/441,521 US44152109A US2011027832A1 US 20110027832 A1 US20110027832 A1 US 20110027832A1 US 44152109 A US44152109 A US 44152109A US 2011027832 A1 US2011027832 A1 US 2011027832A1
Authority
US
United States
Prior art keywords
pcr
blood
soil
dye
polymerase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/441,521
Other languages
English (en)
Inventor
Milko B. Kermekchiev
Lyubka Kirilova
Zhian Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DNA Polymerase Technology Inc
Original Assignee
DNA Polymerase Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DNA Polymerase Technology Inc filed Critical DNA Polymerase Technology Inc
Priority to US12/441,521 priority Critical patent/US20110027832A1/en
Assigned to DNA POLYMERASE TECHNOLOGY, INC. reassignment DNA POLYMERASE TECHNOLOGY, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KIRILOVA, LYUBKA, KERMEKCHIEV, MILKO B., ZHANG, ZHIAN
Publication of US20110027832A1 publication Critical patent/US20110027832A1/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: DNA POLYMERASE TECHNOLOGY, INC.
Priority to US14/746,982 priority patent/US9796965B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Definitions

  • Sequence Listing which is a part of the present disclosure, includes a computer readable form, filed electronically via EFS-Web, comprising nucleotide and/or amino acid sequences of the present invention.
  • the subject matter of the Sequence Listing is incorporated herein by reference in its entirety.
  • the present invention generally relates to nucleic acid detection in standard and real-time PCR and RT PCR.
  • PCR assays are limited by inhibitors found in many common sample types as well as components of the PCR assays themselves.
  • examples of PCR inhibitors include those found in commercial dyes used in PCR as well as those found in blood and soil.
  • Commonly used fluorescent dyes can significantly inhibit the Taq polymerase (GenBank Accession No. J04639; SEQ ID NO: 4) at concentrations higher than about 0.25-1 ⁇ .
  • This dye inhibition of Taq polymerase imposes limitations on the sensitivity and product specificity and may cause dye-dependant false negative results (see e.g., Monis et al. (2005) Anal Biochem 340, 24-34; Stubner (2002) J Microbiol Methods 50, 155-64; Nath et al. (2000) J Biochem Biophys Methods 42, 15-29; Gundry et al. (2003) Clin. Chem. 2003; 49:396-406).
  • humic acid known as the most potent soil inhibitor to PCR analysis.
  • Humic substances represent a mixture of partially characterized polyphenols that are produced during the decomposition of organic matter.
  • Other inhibitory components include fulvic acid, polysaccharides and metal ions that can be present in varying concentrations in the soil samples (see e.g., Tsai et al. (1992) Environ. Microbiol. 58, 2292-2295; Watson et al (2000) Can. J. Microbiol. 46, 633-642; Yeates et al. (1998) Biol. Proced. Online 1, 40-47; LaMontagne et al. (2001) Journal of Microbiological Methods 49, 255-264).
  • a general technical problem with the soil samples is the high variation in the concentrations of various inhibitory substances, depending on the soil source, which may generate inconsistent results. This fact significantly complicates the development of standard DNA purification protocol for processing the samples before PCR. Unlike blood, crude soil extracts exhibit relatively little or no fluorescence quenching effect in real-time PCR.
  • U.S. patent application Ser. No. 11/005,559 (incorporated herein by reference in its entirety) describes blood-resistant mutants of Taq DNA polymerase, which can be used to amplify the DNA target directly in blood in standard, non-real-time PCR. Unlike existing protocols, this method requires no DNA purification steps prior to PCR, thus reducing the time and cost of important clinical blood tests.
  • the blood however, has a strong quenching effect on the fluorescence detected in real-time PCR, and such problem has previously been solved by using higher fluorescent dye concentrations.
  • One aspect provides a method of amplifying a target nucleic acid in a real-time polymerase chain reaction (PCR).
  • the method can include forming an assay mixture comprising a sample, where the sample comprises a target nucleic acid; a plurality of primers specific for the target nucleic acid; a buffer suitable for real-time PCR; at least one dye; and at least one polymerase having dye-resistant activity.
  • the method can include amplifying the target nucleic acid in the assay mixture in a real-time PCR.
  • the target nucleic acid is a DNA molecule. In some embodiments, the target nucleic acid is an RNA molecule. In some embodiments, the real-time PCR is a real-time reverse transcriptase (RT) PCR. In some embodiments, the target nucleic acid is an RNA and the real-time PCR is a real-time reverse transcriptase (RT) PCR. In some embodiments, the target nucleic acid is an RNA; the real-time PCR is a real-time reverse transcriptase (RT) PCR; and the assay mixture further comprises a reverse-transcriptase
  • the at least one polymerase is a dye-resistant and blood-resistant polymerase. In some embodiments, the at least one polymerase is a dye-resistant and soil-resistant polymerase. In some embodiments, the at least one polymerase is a dye-resistant, blood-resistant, and soil-resistant polymerase.
  • the at least one polymerase has a polypeptide sequence comprising SEQ ID NO: 1. In some embodiments, the at least one polymerase has a polypeptide sequence at least 95% identical to SEQ ID NO: 1 and polymerase activity. In some embodiments, the at least one polymerase has a polypeptide sequence at least 95% identical to SEQ ID NO: 1; comprises at least one amino acid substitution at an amino acid residue position selected from the group consisting of positions 626, 707, and 708; and has polymerase activity.
  • the at least one polymerase has a polypeptide sequence comprising SEQ ID NO: 2. In some embodiments, the at least one polymerase has a polypeptide sequence at least 95% identical to SEQ ID NO: 1 and dye-resistant polymerase activity. In some embodiments, the at least one polymerase having a polypeptide sequence at least 95% identical to SEQ ID NO: 2 comprises at least one amino acid substitution at an amino acid residue position selected from the group consisting of 626, 707, and 708.
  • the sample further comprises whole blood or a blood component.
  • the blood component is blood plasma or blood serum.
  • the whole blood is at least about 1% up to about 25% of a total volume of the PCR assay mixture.
  • the blood component is at least about 1% up to about 25% of a total volume of the PCR assay mixture.
  • the sample further comprises soil or soil extract.
  • the soil is at least about 1% up to about 50% of a total volume of the PCR assay mixture.
  • the soil extract is at least about 1% up to about 90% of a total volume of the PCR assay mixture.
  • the soil comprises a humic acid and the soil is present in the assay mixture at a soil equivalent amount that provides up to about 25 ng of humic acid per 50 uL reaction volume.
  • the soil extract comprises a humic acid and the soil extract is present in the assay mixture at a soil extract equivalent amount that provides up to about 25 ng of humic acid per 50 uL reaction volumeor soil extract
  • the at least one dye is a fluorescent dye selected from the group consisting of SYBR Green, Ethidium Bromide, PICO, TOTO, YOYO or LC Green. In some embodiments, the at least one dye is SYBR Green. In some embodiments, the dye is present in the PCR assay mixture at least about 0.5 ⁇ up to about 256 ⁇ , where ⁇ is a manufacturer unit for concentration for use in PCR.
  • the assay mixture further comprises a PCR enhancer.
  • the PCR enhancer comprises betaine.
  • the isolated polypeptide comprises a polypeptide sequence of SEQ ID NO: 2. In some embodiments, the isolated polypeptide comprises a polypeptide sequence at least 95% identical to SEQ ID NO: 2 and having dye-, soil-, or blood-resistant polymerase activity, or a combination thereof. In some embodiments, the isolated polypeptide comprises a polypeptide sequence at least 95% identical to SEQ ID NO: 2 comprising at least one amino acid substitution at an amino acid residue position selected from the group consisting of 626, 707, and 708, and having dye-, soil-, or blood-resistant polymerase activity, or a combination thereof.
  • Another aspect provides a method of amplifying a target nucleic acid in a polymerase chain reaction (PCR) comprising forming an assay mixture comprising a sample comprising a target nucleic acid, wherein the sample optionally contains whole blood or a blood component selected from blood plasma or blood serum, or soil or soil extract; primers specific for the target nucleic acid; a buffer; at least one polymerase described above; and amplifying the target nucleic acid in the assay mixture in a PCR.
  • PCR polymerase chain reaction
  • FIG. 1 is a series of images and graphs depicting results of PCR amplification of a 0.6 kbp Bacillus cereus target DNA with wild type KlenTaq and mutant KlenTaq 10 polymerases conducted in the presence of 7 twofold decreasing concentrations of SYBR Green.
  • FIG. 1A is gel electrophoresis analysis.
  • FIG. 1B is melting curve analysis for wild type KlenTaq.
  • FIG. 1C is melting curve analysis for KlenTaq-10. Further details regarding methodology are presented in Example 1.
  • FIG. 2 is a series of images and graphs depicting results of PCR amplification of a 0.6 kbp Bacillus cereus target DNA with mutant FLAC-22 and a commercial enzyme, Fast Start, conducted in the presence of 7 twofold decreasing concentrations of SYBR Green.
  • FIG. 2A is gel electrophoresis analysis.
  • FIG. 2B is melting curve analysis for FLAC-22.
  • FIG. 2C is melting curve analysis for Fast Start. Further details regarding methodology are presented in Example 3.
  • FIG. 3 is a series of images and graphs depicting results of PCR amplification of an exogenous 0.6 kbp Bacillus cereus target DNA with wild type KlenTaq and mutant KlenTaq10 polymerases in the presence of 5 and 10% blood in addition to very high concentrations of SYBR with subsequent decreasing amounts of SYBR.
  • FIG. 3A is gel electrophoresis analysis.
  • FIG. 3B is melting curve analysis for wild type KlenTaq with 10% blood.
  • FIG. 3C is melting curve analysis for wild type KlenTaq with 5% blood.
  • FIG. 3D is melting curve analysis for KlenTaq-10 with 10% blood.
  • FIG. 3E is melting curve analysis for KlenTaq-10 with 5% blood. Further details regarding methodology are presented in Example 3.
  • FIG. 4 is a series of images and graphs depicting results of PCR amplification of an exogenous 0.32 kbp 16 S microbial target DNA with FLAC-22 and Fast Start Taq polymerases in the presence of constant 5% blood (excluding the positive control) and decreasing amounts SYBR green.
  • FIG. 4A is gel electrophoresis analysis.
  • FIG. 4B is a melting curve analysis for FLAC-22.
  • FIG. 4C is a melting curve analysis for Fast Start. Further details regarding methodology are presented in Example 4.
  • FIG. 5 is a series of images and graphs depicting results of PCR amplification with FLAC-22, KlenTaq-10, Fast Start, Jump Start, and AmpliTaq Gold Taq polymerases in the presence of 6 two-fold decreasing concentrations of SYBR green.
  • FIG. 5A is a gel electrophoresis analysis of FLAC-22 and KlenTaq-10.
  • FIG. 5B is a gel electrophoresis analysis of Fast Start and Jump Start.
  • FIG. 5C is a gel electrophoresis analysis of AmpliTaq Gold.
  • FIG. 5D is a melting curve analysis of FLAC-22.
  • FIG. 5E is a melting curve analysis of KlenTaq-10.
  • FIG. 5F is a melting curve analysis of Fast Start.
  • FIG. 5G is a melting curve analysis of Jump Start.
  • FIG. 5H is a melting curve analysis of AmpliTaq Gold. Further details regarding methodology are presented in Example 5.
  • FIG. 6 is a series of graphs illustrating a successful real-time PCR detection of an anthrax genome target (1.3 kb Bacillus anthracis ) at 5-fold dilutions in 5% human blood, with FLAC-22 mutant enzyme, using 32 ⁇ SYBR Green concentration to compensate for the quenching effect of blood on the fluorescent dye.
  • FIG. 6A is a quantitation graph showing fluorsescence as a function of PCR cycle.
  • FIG. 6B is a standard curve graph showing the log of fluorescence quantity as a function of PCR cycle.
  • FIG. 6C is a melting curve graph. Further details regarding methodology are presented in Example 6.
  • FIG. 7 is a series of graphs and images depicting the high resistance of Klentaq-10 to PCR inhibitors in soil.
  • Various amounts of a crude soil extract were added to the reaction mixture and a test target from a soil-born bacteria, Bacillus Cereus , was amplified successfully with the mutant enzyme, while two commercial wild-type Taq enzymes failed.
  • FIG. 7A shows fluorescence as a function of cycle for Fast Start.
  • FIG. 7B shows fluorescence as a function of cycle for Jump Start.
  • FIG. 7C shows fluorescence as a function of cycle for KlenTaq-10.
  • FIG. 7D is a gel electrophoresis analysis of Fast Start and Jump Start.
  • FIG. 7E is a gel electrophoresis analysis of KlenTaq-10. Further details regarding methodology are presented in Example 7.
  • FIG. 8 is a series of images and graphs depicting the soil inhibition resistance feature of the two novel mutant enzymes, Klentaq-10 and FLAC-22.
  • a real-time PCR assay of a human (CCR5 gene) target was performed in the presence of a crude soil extract mixed with the DNA template.
  • FIG. 8A is a gel electrophoresis analysis of wild type KlenTaq and KlenTaq-10.
  • FIG. 8B is a melting curve graph for wild type KlenTaq.
  • FIG. 8C is a melting curve graph for wild type KlenTaq-10.
  • FIG. 8D is a gel electrophoresis analysis of FLAC-22 and Fast Start.
  • FIG. 8E is a melting curve graph for FLAC-22.
  • 8F is a melting curve graph for Fast Start.
  • the two mutant enzymes outperformed the respective wild-type enzymes, Klentaq and Taq, in tolerating higher soil concentrations.
  • the SYBR Green concentration was titrated to optimize the fluorescent signal for real-time detection. Further details regarding methodology are presented in Example 8.
  • FIG. 9 is a series of agarose gel images depicting results of FLAC-22 and KT-10 (SEQ ID NO: 1) in real-time RT-PCR in crude sample. 100 units of MMLV RT were mixed with 1 unit FLAC-22 and 1 unit KT-10 (SEQ ID NO: 1). The negative controls contained only FLAC-22 and KT-10 (SEQ ID NO: 1) mix and MMLV-RT was omitted ( FIG. 9C ). One commercial RT-PCR kit was also included as a comparison ( FIG. 9B ). Seven pg of influenza virus RNA was spiked in plasma, serum, or whole blood.
  • RT-PCR reactions 50 ⁇ l containing 8% of the blood, serum, or plasma samples mixed with viral RNA were performed in PTC-200 Thermal Cycler to amplify a 244 bp influenza virus RNA target ( FIG. 9A ).
  • the PCR products were resolved in 1.5% agarose gel. Further details regarding methodology are presented in Example 10.
  • FIG. 10 is a series of graphs depicting performance of FLAC-22 and KT-10 (SEQ ID NO: 1) in real-time RT-PCR TaqMan assay in crude sample.
  • Purified influenza virus RNA was 10-fold diluted 7 times and spiked in human serum.
  • FIG. 10A depicts one-step RT-PCR reactions (25 ⁇ l) containing different concentrations of RNA and constant concentrations of human serum (5%), performed with an enzyme mix of 100 units of MMLV RT and 1 unit of FLAC-22 and 2.5 units of KT-10 (SEQ ID NO: 1).
  • FIG. 10B depicts parallel reactions (to those of FIG. 10A ) with purified viral RNA alone included as comparison and positive controls. The negative controls contained no RNA template.
  • a 244 bp influenza virus target was amplified in the presence of a 200 ⁇ M TaqMan probe.
  • the reactions were performed in an Opticon-2 real-time PCR cycler and the fluorescence signal was detected after the annealing step. Further details regarding methodology are presented in Example 11.
  • mutant DNA polymerase enzymes are resistant to PCR inhibitors.
  • mutant DNA polymerase enzymes are resistant to PCR inhibitors including those present in, for example, blood, soil, and/or high concentrations of dyes (e.g., fluorescent dyes used in real-time PCR).
  • dyes e.g., fluorescent dyes used in real-time PCR.
  • Some embodiments of the mutant DNA polymerase enzymes exhibit all three features; therefore they are capable of amplifying nucleic acid molecules in the presence of elevated concentrations of any of these inhibitory substances, or combinations thereof.
  • Provided herein are methods for standard and real-time PCR analyses of blood- and soil-containing samples utilizing mutant polymerase enzymes that are blood-, soil- and/or dye-resistant.
  • mutant DNA polymerase enzymes described herein can allow, in many cases, eliminating nucleic acid purification steps prior to PCR, which are required in the protocols of all currently available commercial PCR enzymes. In clinical applications, this can result in detection at early onset while reducing the number of false negative diagnoses.
  • the dye-, blood-, and/or soil-resistant mutant DNA polymerase enzymes described herein signify a valuable tool for an improved, low-cost, fast, and sensitive PCR detection (including real-time PCR detection) of nucleic acids in general, as well as clinical and forensic applications in specimens with and without crude samples comprising blood or soil extracts.
  • One aspect of the invention is the use of inhibition-resistant mutant DNA polymerase enzymes in real-time PCR assays with crude samples containing, for example, blood and dye, soil and dye, or combination of blood and soil plus dye.
  • blood components e.g., heme
  • PCR assays with conventional DNA polymerases both blood and increased dye concentration are inhibitory.
  • the compositions and methods described herein provide for the use of inhibition resistant mutant polymerase enzymes in real-time PCR applications with blood- or soil-containing samples with dye in PCR reaction mixtures.
  • Another aspect of the invention is the use of inhibition-resistant mutant DNA polymerase enzymes in standard (i.e., non-real time) PCR assays with crude samples containing, for example, blood, soil, or a combination of blood and soil.
  • One aspect of the invention provides a method for improving detection of a target nucleic acid in real-time PCR (qPCR) by using polymerase mutants (e.g., mutant Taq DNA polymerase or mutant Klentaq DNA polymerase) to overcome inhibitory effects of dyes (e.g., fluorescent dyes) used in qPCR.
  • polymerase mutants e.g., mutant Taq DNA polymerase or mutant Klentaq DNA polymerase
  • dyes e.g., fluorescent dyes
  • a resistant polymerase can be used to amplify a DNA target in a real-time PCR of a DNA target in the presence of an inhibitory dye.
  • a resistant polymerase can be used to amplify an RNA target in a real-time reverse transcriptase (RT) PCR of an RNA target in the presence of an inhibitory dye.
  • RT reverse transcriptase
  • mutant polymerase enzymes described herein can tolerate increased concentrations of dyes.
  • increased concentrations include, but are not limited to, up to about 0.5 ⁇ , 1 ⁇ , 1.5 ⁇ , 2 ⁇ , 2.5 ⁇ , 3 ⁇ , 3.5 ⁇ , 4 ⁇ , 4.5 ⁇ , 5 ⁇ , 5.5 ⁇ , 6 ⁇ , 6.5 ⁇ , 7 ⁇ , 7.5 ⁇ , 8 ⁇ , 8.5 ⁇ , 9 ⁇ , 9.5 ⁇ , 10 ⁇ , 15 ⁇ , 20 ⁇ , 25 ⁇ , 30 ⁇ , 35 ⁇ , 40 ⁇ , 45 ⁇ , 50 ⁇ , 55 ⁇ , 60 ⁇ , 65 ⁇ , 70 ⁇ , 80 ⁇ , 90 ⁇ , 100 ⁇ , 150 ⁇ , 200 ⁇ , 250 ⁇ , or even higher (see e.g., FIGS.
  • X can be the standard manufacturers unit for dye concentration provided in a commercial product (e.g., SYBR Green, Molecular Probes, Eugene, Oreg.).
  • SYBR Green Molecular Probes, Eugene, Oreg.
  • X corresponds to a concentration of about 5 to about 10 ⁇ M.
  • Dye tolerance of a mutant polymerase enzyme can provide, for example, higher amplification rate, higher fluorescent signal, and/or increased efficiency as compared to standard concentrations of dyes.
  • Dye-tolerant mutant enzymes can improve the detection of the amplification target, especially when having low copy number of the nucleic acid target.
  • higher dye inhibition resistance can permit enough dye (e.g., SYBR dye) in real time reactions to overcome the background fluorescence or quenching effect of PCR inhibitors, thus permitting detection of a target nucleic acid amongst inhibitors (e.g., components in blood and soil).
  • Dyes for use in the methods described herein include, but are not limited to, SYBR Green (Molecular Probes, Eugene, Oreg.), LC Green (Idaho Technology, Salt Lake City, Utah), PicoGreen (Molecular Probes, Eugene, Oreg.,), TOTO (Molecular Probes, Eugene, Oreg.), YOYO (Molecular Probes, Eugene, Oreg.) and SYTO9 (Molecular Probes, Eugene, Oreg.).
  • the mutant polymerases described herein can outperform other conventional polymerase enzymes, including top commercial PCR enzymes, with commercially available dyes used in qPCR including, but not limited to, SYBR Green (see e.g., FIGS. 1A , 2 A, 2 B, and 8 )), LC Green (Idaho Technology, Salt Lake City, Utah), PICO, TOTO (Molecular Probes, Eugene, Oreg.), YOYO (Molecular Probes, Eugene, Oreg.), SYTO (Molecular Probes, Eugene, Oreg.), and ethidium bromide. Some of these dyes are even more inhibitory than SYBR Green to a conventional Taq enzyme in PCR.
  • resistant polymerases described herein can amplify a target nucleic acid in the presence of blood or blood components.
  • a resistant polymerase can be used to amplify a DNA target in a real-time PCR of a DNA target in the presence of blood or blood components.
  • a resistant polymerase can be used to amplify an RNA target in a real-time reverse transcriptase (RT) PCR of an RNA target in the presence of blood or blood components.
  • RT reverse transcriptase
  • Blood generally comprises plasma, serum, and blood cells.
  • Blood components include, but are not limited to, red blood cells, white blood cells (e.g., leukocytes or platelets, i.e., thrombocytes), plasma, serum, hemoglobin, water, proteins, glucose, amino acids, fatty acids, mineral ions, hormones, carbon dioxide, urea, and lactic acid.
  • Resistant polymerases described herein can be used in PCR to amplify a nucleic acid target in the presence of one or more such blood components.
  • Blood plasma is generally understood as a liquid suspension in which blood cells are circulated.
  • blood plasma can include one or more of water, proteins, glucose, amino acids, fatty acids, mineral ions, hormones, carbon dioxide, urea, lactic acid, platelets (i.e., thrombocytes), and blood cells.
  • blood plasma represents about 55% of whole blood, or about 2.7 to 3 liters in an average human subject.
  • Blood plasma contains about 92% water, 8% blood plasma proteins, and trace amounts of other materials.
  • Blood plasma can contain serum albumin, blood-clotting factors, immunoglobulins, lipoproteins, other proteins, and electrolytes (e.g., sodium and chloride).
  • a crude sample comprising blood plasma can also contain blood cells. Resistant polymerases described herein can be used in PCR to amplify a nucleic acid target in the presence of blood plasma.
  • Blood serum is generally understood as plasma from which clotting proteins have been removed, leaving mostly albumin and immunoglobulins.
  • Resistant polymerases described herein can be used in PCR to amplify a nucleic acid target in the presence of blood serum.
  • a blood-resistant polymerase can generally display amplification activity in PCR assays (e.g., real-time PCR or real-time RT PCR) containing from about 1% to about 25% whole blood in the reaction mixture (vol/vol).
  • whole blood can comprise at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, or 25% of a total volume of a PCR assay mixture comprising a blood-resistant polymerase described herein.
  • the full-length Taq enzyme (SEQ ID NO: 4) is usually completely inhibited in a blood concentration range of about 0.004% to about 0.2% whole blood in the reaction mixture (vol/vol).
  • a resistant polymerase can generally display amplification activity in PCR assays (e.g., real-time PCR or real-time RT PCR) containing from about 1% to about 25% of a blood component in the reaction mixture (vol/vol).
  • a blood component can comprise at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, or 25% of a total volume of a PCR assay mixture comprising a blood-resistant polymerase described herein.
  • a resistant polymerase can generally display amplification activity in PCR assays (e.g., real-time PCR or real-time RT PCR) containing from about 1% to about 25% blood plasma in the reaction mixture (vol/vol).
  • blood plasma can comprise at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, or 25% of a total volume of a PCR assay mixture comprising a blood-resistant polymerase described herein.
  • a resistant polymerase can generally display amplification activity in PCR assays (e.g., real-time PCR or real-time RT PCR) containing from about 1% to about 25% blood serum in the reaction mixture (vol/vol).
  • blood serum can comprise at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, or 25% of a total volume of a PCR assay mixture comprising a blood-resistant polymerase described herein.
  • Blood-resistance can be readily determined by assays described herein and know in the art (see e.g., US Pat App Pub No 2006/0084074).
  • mutant DNA polymerases described herein are resistant to inhibitors found in soil and soil extracts.
  • resistant polymerases described herein can amplify a target nucleic acid in the presence of an inhibitor found in soil or soil extract.
  • a resistant polymerase can be used to amplify a DNA target in a real-time PCR of a DNA target in the presence of an inhibitor found in soil or soil extract.
  • a resistant polymerase can be used to amplify an RNA target in a real-time reverse transcriptase (RT) PCR of an RNA target in the presence of an inhibitor found in soil or soil extract.
  • RT reverse transcriptase
  • Soil inhibitors and soil extract inhibitors include, but are not limited to, humic acid, fulvic acid, polysaccarides, and metal ions.
  • a soil-resistant polymerase can generally display amplification activity in PCR assays containing from about 1% to about 90% soil or soil extract in the reaction mixture (vol/vol).
  • soil extract can comprise up to about 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 1% of a total volume of a PCR assay mixture comprising a soil-resistant DNA polymerase described herein.
  • soil extract can comprise up to about 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 1% of a total volume of a PCR assay mixture comprising a soil-resistant DNA polymerase described herein.
  • the amount of soil or soil extract in the assay mixture can depend upon the levels of inhibitory substances in the soil or soil extract.
  • the mutant DNA polymerases described herein can tolerate at least an order of magnitude greater concentration of these inhibitory substances, as compared to conventional DNA polymerases.
  • Assays to determine the level of inhibitory substances in a sample are known in the art. Soil-resistance can be readily determined by assays described herein.
  • humic acid Direct extraction of total DNA from soil samples results in a co-extraction of humic acid, known as the most potent soil inhibitor to PCR analysis.
  • Humic substances represent a mixture of partially characterized polyphenols that are produced during the decomposition of organic matter.
  • Conventional DNA polymerase enzymes are inhibited at about 1 ng of humic acid per 50 uL reaction volume.
  • Various embodiments of the mutant DNA polymerases described herein are resistant to soil or soil extract that contains, for example, various levels of humic acid.
  • the volume of soil or soil extract used in the PCR assay mixture is the soil or soil extract equivalent that provides up to about 25 ng of humic acid per 50 uL reaction volume.
  • the volume of soil or soil extract used in the PCR assay mixture is the soil or soil extract equivalent that provides up to about 20 ng of humic acid per 50 uL reaction volume, more preferably up to about 10 ng of humic acid per 50 uL reaction volume.
  • the mutant polymerase enzymes are resistant to both blood and dye (e.g., fluorescent dye) inhibition; soil and dye inhibition; or blood, soil and dye inhibition, as might occur in, for example, a PCR reaction containing dye and blood and/or soil.
  • blood and dye e.g., fluorescent dye
  • soil and dye inhibition e.g., soil and dye inhibition
  • blood, soil and dye inhibition e.g., blood, and dye inhibition
  • a synergy is provided in which the combination of the mutant enzymes, blood, and fluorescent dyes enable amplification and optical detection heretofore not possible.
  • a preferred double inhibition resistant phenotype (i.e., blood and dye resistance) of a mutant enzyme makes possible the real-time detection of samples containing blood.
  • the blood- and dye-resistant mutant polymerases can tolerate higher initial concentration of dye (e.g., tolerance of about 64 ⁇ to about 256 ⁇ for SYBR Green dye).
  • resistant polymerases described herein can amplify a target nucleic acid in the presence of an inhibitory dye and an inhibitor found in soil or soil extract; an inhibitory dye and blood or a blood component; or an inhibitory dye, an inhibitor found in soil or soil extract, and blood or a blood component.
  • a resistant polymerase can be used to amplify a DNA target in a real-time PCR of a DNA target in the presence of an inhibitory dye and an inhibitor found in soil or soil extract; an inhibitory dye and blood or a blood component; or an inhibitory dye, an inhibitor found in soil or soil extract, and blood or a blood component.
  • a resistant polymerase can be used to amplify an RNA target in a real-time reverse transcriptase (RT) PCR of an RNA target in the presence of an inhibitory dye and an inhibitor found in soil or soil extract; an inhibitory dye and blood or a blood component; or an inhibitory dye, an inhibitor found in soil or soil extract, and blood or a blood component.
  • RT real-time reverse transcriptase
  • Interference between the blood and the fluorescent dye is demonstrated herein to at least partially eradicate the detection of the amplified product when using normal (i.e., low) dye concentrations (e.g., 1 ⁇ or lower for SYBR Green).
  • dye concentrations e.g. 1 ⁇ or lower for SYBR Green.
  • Adding high dye concentration to the reaction can help to overcome the quenching effect of blood components (e.g., heme) on the dye fluorescence.
  • a resistant polymerase can be employed in a real-time PCR amplification of a DNA target.
  • the DNA polymerases resistant to PCR inhibitors described herein can be used in a variety of polymerase reactions known to the art (see e.g., Dorak (2006) Real-Time PCR, Taylor & Francis, ISBN 041537734X; Bustin, ed. (2004) A-Z of Quantitative PCR, International University Line, ISBN 0963681788).
  • the resistant polymerases can be employed in PCR reactions, primer extension reactions, etc.
  • the use of the mutant polymerase enzymes described herein generally does not require any, or substantial, changes in the typical protocol, other than, for example, adding higher amounts of fluorescent dye.
  • methods described herein can be applied to improve the nucleic acid detection in any standard real-time PCR with purified template nucleic acids and primers.
  • a resistant polymerase can be employed in a real-time reverse transcriptase (RT) PCR amplification of an RNA target.
  • RT reverse transcriptase
  • Q-PCR real-time polymerase chain reaction
  • an RNA strand is first reverse transcribed into its DNA complement (complementary DNA, or cDNA) using the enzyme reverse transcriptase, and the resulting cDNA is amplified using traditional PCR.
  • RT-PCR uses RNA virus pathogens to detect RNA virus pathogens.
  • analysis of mRNA expression patterns of certain genes related to various diseases include, but are not limited to, detection of RNA virus pathogens; analysis of mRNA expression patterns of certain genes related to various diseases; semiquantitative determination of abundance of specific different RNA molecules within a cell or tissue as a measure of gene expression; and cloning of eukaryotic genes in prokaryotes.
  • Resistant polymerases described herein can be used in a variety of RT-PCR protocols known to the art (see e.g., King and O'Connel (2002) RT-PCR Protocols, 1 st Ed., Human Press, ISBN-10 0896038750).
  • the use of the mutant polymerase enzymes described herein generally does not require any, or substantial, changes in the typical protocol, other than, for example, adding higher amounts of a fluorescent dye.
  • methods described herein can be applied to improve target detection in any standard RT PCR.
  • the buffer for use in the various PCR assay mixtures described herein is generally a physiologically compatible buffer that is compatible with the function of enzyme activities and enables cells and/or biological macromolecules to retain their normal physiological and biochemical functions.
  • a physiologically compatible buffer will include a buffering agent (e.g., TRIS, MES, PO 4 , HEPES, etc.), a chelating agent (e.g., EDTA, EGTA, or the like), a salt (e.g., ammonium sulfate, NaCl, KCl, MgCl.sub.2, CaCl.sub.2, NaOAc, KOAc, Mg(OAc).sub.2, etc.) and optionally a stabilizing agent (e.g., sucrose, glycerine, Tween20, etc.).
  • a buffering agent e.g., TRIS, MES, PO 4 , HEPES, etc.
  • a chelating agent e.g., EDTA
  • betaine can be added to the PCR assay, to further aid in overcoming the inhibition by blood and/or soil.
  • Betaine can be included at final concentration about 1 M to about 2M.
  • betaine alone is insufficient to overcome the inhibition of, for example, dye, blood, and/or soil when used with conventional DNA polymerases.
  • mutant enzymes useful to the invention include, but are not limited to, KlenTaq-10 (SEQ ID NO: 1) (as described in US Pat App Pub No 2006/0084074, specifically incorporated herein by reference in its entirety) and the full-length Taq enzyme mutant, FLAC-22 (SEQ ID NO: 2), as well as variant polypeptides of these reference sequences, as described below.
  • position number 1 as notated in the Sequence Listing of SEQ ID NO: 1 or SEQ ID NO: 3 corresponds to position number 279 as notated in the full-length Taq of SEQ ID NO: 4.
  • position number 2 of SEQ ID NO:1 or SEQ ID NO: 3 corresponds to position number 280 of SEQ ID NO: 4.
  • KlenTaq-1 (SEQ ID NO: 3) has an N-terminal deletion at 278 of a full-length Taq (SEQ ID NO: 4), with Met/Gly replacing amino acids 279 and 280 (per wild type Taq numbering). It is noted that Klentaq-1 is a “wild-type” Klentaq given that it is directly derived from wild-type Taq by truncation.
  • KlenTaq-10 (SEQ ID NO: 1) has an N-terminal deletion at 278 of a full-length wild type Taq (SEQ ID NO: 4) and substitutions at E626K, I707L, and E708K (per wild type Taq numbering).
  • FLAC22 (SEQ ID NO: 2) is a full-length Taq (SEQ ID NO: 4) with substitutions at E626K, 1707L, and E708N (per wild type Taq numbering).
  • variant polypeptides or encoding polynucleotides with at least 80% sequence identity to the above-described sequences, so long as such variants retain dye-resistant polymerase activity; dye- and blood-resistant polymerase activity; dye- and soil-resistant polymerase activity; or dye-, blood-, and soil-resistant polymerase activity.
  • variant polypeptides with dye-resistant polymerase activity; dye- and blood-resistant polymerase activity; dye- and soil-resistant polymerase activity; or dye-, blood-, and soil-resistant polymerase activity can have at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.9% sequence identity to sequences disclosed herein.
  • variant polypeptides (or encoding polynucleotides) with dye-resistant polymerase activity; dye- and blood-resistant polymerase activity; dye- and soil-resistant polymerase activity; or dye-, blood-, and soil-resistant polymerase activity have at least 95% sequence identity to sequences disclosed herein. More preferably, variant polypeptides (or encoding polynucleotides) with dye-; dye- and blood-; dye- and soil-; or dye-, blood- and soil-resistant polymerase activity have at least 99% sequence identity to sequences disclosed herein.
  • SEQ ID NO: 1 and SEQ ID NO: 2 are representative of the genus of variant polypeptides of each of these respective sequences because all variants must possess the specified catalytic activity (e.g., dye-, blood-, and/or soil-resistant polymerase activity) and must have the percent identity required above to the reference sequence.
  • catalytic activity e.g., dye-, blood-, and/or soil-resistant polymerase activity
  • polypeptide variants having, for example, at least 95-99% identity to the sequences of mutant DNA polymerases described herein and screen such for phenotypes including, dye-resistance, blood-resistance, and/or soil-resistance according to methods routine in the art.
  • conservative substitutions can be made at any position so long as the required activity is retained.
  • Amino acid positions known to be associated with the phenotypes described herein include, but are not limited to 626, 707, and 708 (per wild type Taq numbering) (see Example 9).
  • substitutions at 708 include K and L for truncated and full length mutant Taq polymerases; N, Q, and I for full length mutant Taq polymerases; and W in truncated mutant Taq polymerases.
  • Preferable substitutions include E708R and E708L.
  • Amino acid sequence identity percent is understood as the percentage of amino acid residues that are identical with amino acid residues in a candidate sequence in comparison to a reference sequence when the two sequences are aligned. To determine percent amino acid identity, sequences are aligned and if necessary, gaps are introduced to achieve the maximum percent sequence identity; conservative substitutions are not considered as part of the sequence identity. Amino acid sequence alignment procedures to determine percent identity are well known to those of skill in the art. Often publicly available computer software such as BLAST, BLAST2, ALIGN2 or Megalign (DNASTAR) software is used to align peptide sequences. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared.
  • Mutant DNA polymerases described herein can be produced according to methods known in the art.
  • oligonucleotides providing the specific amino acid changes to a mutant DNA polymerase described can be prepared by standard synthetic techniques (e.g., an automated DNA synthesizer) and used as PCR primers in site-directed mutagenesis. Standard procedures of expression of mutant DNA polymerase polypeptides from encoding DNA sequences can then be performed.
  • the mutant DNA polymerase polypeptides can be directly synthesized according to methods known in the art.
  • primer oligonucleotides were used in real-time PCR reaction to amplify a 0.6 kbp Bacillus cereus specific target from 20 pg input genomic DNA: forward 5′-AGG GTC ATT GGA AAC TGG G-3′ (SEQ ID NO 5), and reverse 5′-CGT GTT GTA GCC CAG GTC ATA-3′ (SEQ ID NO 6).
  • the final concentration of each primer was 0.2 uM used in a common master mix.
  • the amount of each enzyme used was 2.5 units per 50 ul reaction. Wild type KlenTaq and mutant KlenTaq-10 were challenged with a series of seven two-fold SYBR green fluorescent dye dilutions starting with 16 ⁇ concentration. After 40 cycles the products were analyzed both in 2% agarose gel electrophoresis (see e.g., FIG. 1A ) and temperature dissociation profile (see e.g., FIG. 1B ).
  • Results show that KlenTaq-10 was capable of amplifying a 0.6 kbp Bacillus cereus target DNA in the presence of 4 ⁇ SYBR, while the wild type failed at concentrations higher than 1 ⁇ (see e.g., FIG. 1 ).
  • the post PCR melting curve analysis confirms the fluorescent detection and the specificity of the product.
  • primer oligonucleotides were used in real-time PCR reaction to amplify a 0.6 kbp Bacillus cereus specific target from 20 pg input genomic DNA: forward 5′-AGG GTC ATT GGA AAC TGG G-3′ (SEQ ID NO 5), and reverse 5′-CGT GTT GTA GCC CAG GTC ATA-3′ (SEQ ID NO 6).
  • the final concentration of each primer was 0.2 uM used in a common master mix.
  • the amount of each enzyme used was 2.5 units per 50 ul reaction.
  • FLAC-22 SEQ ID NO: 2
  • Fast Start Tags were challenged with a series of seven two-fold SYBR green fluorescent dye dilutions starting with 6.4 ⁇ concentration. After 40 cycles the products were analyzed both in 2% agarose gel electrophoresis (see e.g., FIG. 2A ) and temperature dissociation profile (see e.g., FIG. 2B ).
  • primer oligonucleotides were used in real-time PCR reaction to amplify a 0.6 kbp Bacillus cereus specific target from 20 pg input genomic DNA: forward 5′-AGG GTC ATT GGA AAC TGG G-3′ (SEQ ID NO: 5), and reverse 5′-CGT GTT GTA GCC CAG GTC ATA-3′ (SEQ ID NO: 6).
  • the final concentration of each primer was 0.2 uM used in a common master mix.
  • the amount of each enzyme used was 2.5 units per 50 ul reaction.
  • Wild-type KlenTaq and KlenTaq-10 were double challenged with two blood concentrations 5% and 10% of the total reaction volume and with series of six two-fold SYBR green fluorescent dye dilutions starting with 64 ⁇ concentration. After 40 cycles, the products were analyzed both in 2% agarose gel electrophoresis (see e.g., FIG. 3A ) and temperature dissociation profile (see e.g., FIG. 3B ).
  • KlenTaq 10 was capable of amplifying with at least two times higher concentration of SYBR compared to the wild type KlenTaq (see e.g., FIG. 3 ).
  • the post PCR melting curve analysis confirms that in the presence of 10% blood, at least 8 ⁇ SYBR green is necessary for real-time PCR detection and at least 2 ⁇ SYBR for 5% blood samples. Results also show that the resistance of KlenTaq 10 toward SYBR green is increased to at least 64 ⁇ compared to 4 ⁇ when there is no blood in the reaction.
  • primer oligonucleotides were used in real-time PCR reaction to amplify a 0.32 kbp 16S microbial target: forward 5′-GGA TGC AAG CGT TAT CCG GAA TG-3′ (SEQ ID NO 7), and reverse 5′-CAT TCT TGC GAA CGT ACT CCC CA-3′ (SEQ ID NO 8).
  • the final concentration of each primer was 0.2 uM used in a common master mix.
  • the amount of each enzyme used was 2.5 units per 50 ul reaction.
  • FLAC-22 (SEQ ID NO: 2) and Fast Start Tags were double challenged with 5% blood and with a series of four two-fold SYBR green fluorescent dye dilutions and no SYBR control starting with 32 ⁇ concentration.
  • a positive control a reaction containing neither blood nor SYBR, was also included. After 40 cycles, the products were analyzed both in 2% agarose gel electrophoresis (see e.g., FIG. 4A ) and temperature dissociation profile (see e.g., FIG. 4B ).
  • primer oligonucleotides were used in real-time PCR reaction to amplify a 0.25 kbp Lambda specific target: forward 5′-GGG CGG CGA CCT CGC GGG TTT TCG C-3′ (SEQ ID NO 9), and reverse 5′-CTG AAT GGT ACG GAT ACT CGC ACC G-3′ (SEQ ID NO 10).
  • the final concentration of each primer was 0.2 uM used in a common master mix.
  • the amount of each enzyme used was 2.5 units per 50 ul reaction.
  • results showed that FLAC-22 (SEQ ID NO: 2) was capable of amplifying a 0.25 kbp lambda target from added purified DNA template in the presence of 2 ⁇ SYBR; and KlenTaq-10 was able to amplify with at least 4 ⁇ SYBR; but the commercial Taq polymerases failed at concentrations higher than 0.5 ⁇ (see e.g., FIG. 5 ).
  • the post PCR melting curve analysis confirms the fluorescent detection and the specificity of the product.
  • KT-10 mutant enzyme SEQ ID NO: 1
  • the reactions contained four dilutions of the soil extract: 16%, 8%, 4% and 2% (see e.g., FIG. 7D-E , lanes 1-4, respectively).
  • Reactions in lane 5 were positive controls, containing 5 ng purified B. cereus DNA without soil extract.
  • PCR was performed in real-time cycler Opticon-2, and the amplified products were analyzed both by SYBR Green dye fluorescence (top panels) and gel electrophoresis (bottom panels).
  • the pink curves correspond to the control reactions and the yellow, blue, green, and red ones reflect the reactions with increasing soil concentration.
  • This example demonstrates the soil-resistance feature of the mutant Klentaq-10 enzyme, outperforming the two commercial Tags, which require DNA purification from soil prior to PCR.
  • the soil resistant mutant enzymes showed specific melting curves with very low background signal.
  • the wild type Klentaq and Fast Start Taq showed a melting curve at very low SYBR concentration so the signal might get lost in the background in the presence of more soil.
  • the results demonstrate that the two new mutant enzymes can perform easily in real time PCR of crude soil samples containing PCR inhibitors, without requiring pre-PCR DNA purification steps.
  • Klentaq-10 SEQ ID NO: 1
  • FLAC-22 SEQ ID NO: 2
  • residue 708 was confirmed by the fact that two of the possible 20 substitutions, P and C, inactivated both the KlenTaq and Taq enzyme.
  • the following example illustrates real-time RT PCR amplification of crude samples containing blood components utilizing FLAC-22 (SEQ ID NO: 2) and KT-10 (SEQ ID NO: 1).
  • MMLV RT 100 units of MMLV RT were mixed with 1 unit FLAC-22 (SEQ ID NO: 2) and 1 unit KT-10 (SEQ ID NO: 1).
  • the negative controls only contained FLAC-22 (SEQ ID NO: 2) and KT-10 mix and MMLV-RT was omitted.
  • One commercial RT-PCR kit was also included as comparison. Seven pg of influenza virus RNA was spiked in plasma, serum, or whole blood. RT-PCR reactions also contained an enhancer composition containing 0.64 M Trehalose, 0.12 M L-carnitine, 0.4% NP-40 and 10 u heparin per ml serum, plasma, or whole blood (PEC-Plus).
  • RT-PCR reactions 50 ⁇ l containing viral RNA (lane 1) or viral RNA mixed with 8% of plasma (lane 2), serum (lane 3), or blood (lane 4) were performed in PTC-200 Thermal Cycler to amplify a 244 bp influenza virus RNA target.
  • the PCR products were resolved in 1.5% agarose gel.
  • Results showed a 244 bp influenza virus gene was successivefully amplified from purified RNA and mimic crude samples containing 8% plasma, serum, and whole blood using an FLAC-22 (SEQ ID NO: 2), KT-10 (SEQ ID NO: 1) and MMLV-RT mixture (see e.g., FIG. 9 ). Succesful amplification of RNA targets was also obtained where FLAC-22 (SEQ ID NO: 2) and KT-10 (SEQ ID NO: 1) were blended with other reverse transcriptase (data not shown).
  • FLAC-22 SEQ ID NO: 2
  • KT-10 SEQ ID NO: 1
  • the following example illustrates real-time RT PCR TaqMan assay in crude samples containing blood components utilizing FLAC-22 (SEQ ID NO: 2) and KT-10 (SEQ ID NO: 1).
  • One-step RT-PCR reactions 25 ⁇ l containing different concentrations of RNA and constant concentrations of human serum (5%), were performed with an enzyme mix of 100 units of MMLV RT and 1 unit of FLAC-22 (SEQ ID NO: 2) and 2.5 units of KT-10 (SEQ ID NO: 1).
  • RT-PCR reactions also contained an enhancer composition containing 0.64 M Trehalose, 0.12 M L-carnitine, 0.4% NP-40 and 10 u heparin per ml serum, plasma, or whole blood (PEC-Plus).
  • Parallel reactions with purified viral RNA alone were included as comparison and positive controls.
  • the negative controls contained no RNA template.
  • a 244 bp influenza virus target was amplified in the presence of a 200 ⁇ M TaqMan probe. The reactions were performed in an Opticon-2 real-time PCR cycler and the fluorescence signal was detected after the annealing step.
  • Results showed that the 244 bp influenza virus gene was successfully detected from mimic clinical samples containing 5% human serum, using a combination of FLAC-22 (SEQ ID NO: 2), KT-10 (SEQ ID NO: 1), and MMLV-RT.
  • the fluorescent signal in crude samples was relatively lower than these in purified RNA, however, the sensitivity was not compromised as compared to the results with purified RNA.
  • results were confirmed with plasma and whole blood (data not shown).
  • the optimal concentrations of TaqMan was 200-400 ⁇ M for 5-20% plasma and serum, and 400-8000 for 5-10% whole blood.
  • FLAC-22 SEQ ID NO: 2
  • KT-10 SEQ ID NO: 1

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
US12/441,521 2006-09-14 2009-03-16 Use of taq polymerase mutant enzymes for nucleic acid amplification in the presence of pcr inhibitors Abandoned US20110027832A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/441,521 US20110027832A1 (en) 2006-09-14 2009-03-16 Use of taq polymerase mutant enzymes for nucleic acid amplification in the presence of pcr inhibitors
US14/746,982 US9796965B2 (en) 2006-09-14 2015-06-23 Use of Taq polymerase mutant enzymes for nucleic acid amplification in the presence of PCR inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82569206P 2006-09-14 2006-09-14
PCT/US2007/078571 WO2008034110A2 (en) 2006-09-14 2007-09-14 Use of taq polymerase mutant enzymes for dna amplification in the presence of pcr inhibitors
US12/441,521 US20110027832A1 (en) 2006-09-14 2009-03-16 Use of taq polymerase mutant enzymes for nucleic acid amplification in the presence of pcr inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/078571 Continuation-In-Part WO2008034110A2 (en) 2006-09-14 2007-09-14 Use of taq polymerase mutant enzymes for dna amplification in the presence of pcr inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/746,982 Division US9796965B2 (en) 2006-09-14 2015-06-23 Use of Taq polymerase mutant enzymes for nucleic acid amplification in the presence of PCR inhibitors

Publications (1)

Publication Number Publication Date
US20110027832A1 true US20110027832A1 (en) 2011-02-03

Family

ID=39184635

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/441,521 Abandoned US20110027832A1 (en) 2006-09-14 2009-03-16 Use of taq polymerase mutant enzymes for nucleic acid amplification in the presence of pcr inhibitors
US14/746,982 Active US9796965B2 (en) 2006-09-14 2015-06-23 Use of Taq polymerase mutant enzymes for nucleic acid amplification in the presence of PCR inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/746,982 Active US9796965B2 (en) 2006-09-14 2015-06-23 Use of Taq polymerase mutant enzymes for nucleic acid amplification in the presence of PCR inhibitors

Country Status (6)

Country Link
US (2) US20110027832A1 (https=)
EP (1) EP2061894A4 (https=)
JP (2) JP5457184B2 (https=)
AU (1) AU2007296180A1 (https=)
CA (1) CA2664043A1 (https=)
WO (1) WO2008034110A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014062848A1 (en) * 2012-10-16 2014-04-24 Dna Polymerase Technology, Inc. Inhibition-resistant polymerases
US10052604B2 (en) 2014-07-21 2018-08-21 Agency For Science, Technology And Research Silica coating on nanoparticles
US11091745B2 (en) 2015-05-12 2021-08-17 Dna Polymerase Technology, Inc. Mutant polymerases and uses thereof

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462475B2 (en) 2004-05-20 2008-12-09 Dna Poleymerase Technology, Inc. Use of whole blood in PCR reactions
US20090305345A1 (en) 2006-10-23 2009-12-10 Medical Research Council Polymerase
JP2011097828A (ja) * 2008-07-09 2011-05-19 Beckman Coulter Inc 全血試料の前処理方法及び核酸増幅方法
WO2010062777A2 (en) * 2008-11-03 2010-06-03 Kapabiosystems Modified type a dna polymerases
FI20095729A0 (fi) * 2009-06-26 2009-06-26 Finnzymes Oy Menetelmä deoksiribonukleiinihappojen kvantitatiiviseen PCR-monistukseen PCR-inhibiittoreita sisältävästä näytteestä
WO2011014885A1 (en) * 2009-07-31 2011-02-03 Agilent Technologies, Inc. Thermostable type-a dna polymerase mutants with increased polymerization rate and resistance to inhibitors
FI20096013A7 (fi) * 2009-10-02 2011-04-03 Finnzymes Oy Menetelmä reaktioseoksen valmistelemiseksi ja tähän liittyvät tuotteet
JP5926248B2 (ja) 2010-06-18 2016-05-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 増大した３’末端ミスマッチ識別能を有するｄｎａポリメラーゼ
WO2011157432A1 (en) 2010-06-18 2011-12-22 Roche Diagnostics Gmbh Dna polymerases with increased 3'-mismatch discrimination
EP2582806B1 (en) 2010-06-18 2015-12-16 Roche Diagnostics GmbH Dna polymerases with increased 3'-mismatch discrimination
WO2011157434A1 (en) 2010-06-18 2011-12-22 Roche Diagnostics Gmbh Dna polymerases with increased 3'-mismatch discrimination
US8759062B2 (en) 2010-06-18 2014-06-24 Roche Molecular Systems, Inc. DNA polymerases with increased 3′- mismatch discrimination
WO2011157436A1 (en) 2010-06-18 2011-12-22 Roche Diagnostics Gmbh Dna polymerases with increased 3'-mismatch discrimination
ES2536252T3 (es) 2010-06-18 2015-05-21 F. Hoffmann-La Roche Ag ADN polimerasas con diferenciación de desapareamientos 3' aumentada
CA2802239C (en) 2010-06-18 2016-08-23 F. Hoffmann-La Roche Ag Dna polymerases with increased 3'-mismatch discrimination
WO2012097318A2 (en) 2011-01-14 2012-07-19 Kap Abiosystems Modified dna polymerases for improved amplification
US8765435B2 (en) 2011-02-15 2014-07-01 Roche Molecular Systems, Inc. DNA polymerases with increased 3′-mismatch discrimination
JP5847200B2 (ja) 2011-02-15 2016-01-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 増大した３’末端ミスマッチ識別能を有するｄｎａポリメラーゼ
ES2561885T3 (es) 2011-04-11 2016-03-01 F. Hoffmann-La Roche Ag ADN polimerasas de actividad mejorada
GB201113430D0 (en) 2011-08-03 2011-09-21 Fermentas Uab DNA polymerases
US11208636B2 (en) 2011-08-10 2021-12-28 Life Technologies Corporation Polymerase compositions, methods of making and using same
US20130040365A1 (en) 2011-08-10 2013-02-14 Life Technologies Corporation Polymerase compositions, methods of making and using same
ES2569723T3 (es) 2011-12-08 2016-05-12 F. Hoffmann-La Roche Ag Polimerasas de DNA con actividad mejorada
ES2668448T3 (es) 2011-12-08 2018-05-18 F. Hoffmann-La Roche Ag ADN polimerasas con actividad mejorada
CN103998603B (zh) 2011-12-08 2016-05-25 霍夫曼-拉罗奇有限公司 具有改进活性的dna聚合酶
US9758773B2 (en) * 2014-02-14 2017-09-12 Agilent Technologies, Inc. Thermostable type-A DNA polymerase mutant with increased resistance to inhibitors in blood
WO2021242041A1 (ko) * 2020-05-29 2021-12-02 (주)제노텍 유전자 변이에 대한 구분성이 향상된 dna 중합효소 변이체
JP7393070B1 (ja) * 2023-08-04 2023-12-06 株式会社ゴーフォトン Ｐｃｒ方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436149A (en) * 1993-02-19 1995-07-25 Barnes; Wayne M. Thermostable DNA polymerase with enhanced thermostability and enhanced length and efficiency of primer extension
US5501963A (en) * 1992-09-11 1996-03-26 Hoffmann-La Roche Inc. Amplification and detection of nucleic acids in blood samples
US5616494A (en) * 1990-10-05 1997-04-01 Barnes; Wayne M. Thermus aquaticus DNA polymerase lacking the n-terminal 235 amino acids of taq DNA polymerase
US20040161767A1 (en) * 2002-06-28 2004-08-19 Baldwin Brett R. Detection and quantification of aromatic oxygenase genes by real-time PCR
US6818431B1 (en) * 1995-10-18 2004-11-16 Shanghai Mendel Dna Center Co. Ltd. DNA polymerase having ability to reduce innate selective discrimination against fluorescent dye-labeled dideoxynucleotides
US20050260606A1 (en) * 2004-05-20 2005-11-24 Kermekchiev Milko B Use of whole blood in PCR reactions
US20060084074A1 (en) * 2004-05-20 2006-04-20 Kermekchiev Milko B Use of whole blood in PCR reactions
US20070111234A1 (en) * 2005-09-12 2007-05-17 Christian Birkner Detection of biological DNA

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0022458D0 (en) 2000-09-13 2000-11-01 Medical Res Council Directed evolution method
US20060234227A1 (en) 2002-05-14 2006-10-19 Alexei Slesarev Helix-hairpin-helix motifs to manipulate properties of dna processing enzymes
US7417133B2 (en) 2004-02-27 2008-08-26 Institut Pasteur Methods for obtaining thermostable enzymes, DNA polymerase I variants from Thermus aquaticus having new catalytic activities, methods for obtaining the same, and applications of the same
US20070048748A1 (en) 2004-09-24 2007-03-01 Li-Cor, Inc. Mutant polymerases for sequencing and genotyping

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616494A (en) * 1990-10-05 1997-04-01 Barnes; Wayne M. Thermus aquaticus DNA polymerase lacking the n-terminal 235 amino acids of taq DNA polymerase
US5501963A (en) * 1992-09-11 1996-03-26 Hoffmann-La Roche Inc. Amplification and detection of nucleic acids in blood samples
US5436149A (en) * 1993-02-19 1995-07-25 Barnes; Wayne M. Thermostable DNA polymerase with enhanced thermostability and enhanced length and efficiency of primer extension
US6818431B1 (en) * 1995-10-18 2004-11-16 Shanghai Mendel Dna Center Co. Ltd. DNA polymerase having ability to reduce innate selective discrimination against fluorescent dye-labeled dideoxynucleotides
US20040161767A1 (en) * 2002-06-28 2004-08-19 Baldwin Brett R. Detection and quantification of aromatic oxygenase genes by real-time PCR
US20050260606A1 (en) * 2004-05-20 2005-11-24 Kermekchiev Milko B Use of whole blood in PCR reactions
US20060084074A1 (en) * 2004-05-20 2006-04-20 Kermekchiev Milko B Use of whole blood in PCR reactions
US20090170060A1 (en) * 2004-05-20 2009-07-02 Dna Polymerase Technology Inc. Use of whole blood in pcr reactions
US20070111234A1 (en) * 2005-09-12 2007-05-17 Christian Birkner Detection of biological DNA

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ngo et al. in The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al. (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495. *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014062848A1 (en) * 2012-10-16 2014-04-24 Dna Polymerase Technology, Inc. Inhibition-resistant polymerases
EP3366769A1 (en) 2012-10-16 2018-08-29 DNA Polymerase Technology, Inc. Inhibition-resistant polymerases
US10683537B2 (en) 2012-10-16 2020-06-16 Dna Polymerase Technology, Inc. Inhibition-resistant polymerases
US12305228B2 (en) 2012-10-16 2025-05-20 Dna Polymerase Technology, Inc. Inhibition-resistant polymerases
US10052604B2 (en) 2014-07-21 2018-08-21 Agency For Science, Technology And Research Silica coating on nanoparticles
US11091745B2 (en) 2015-05-12 2021-08-17 Dna Polymerase Technology, Inc. Mutant polymerases and uses thereof
US11814655B2 (en) 2015-05-12 2023-11-14 Dna Polymerase Technology, Inc. Mutant polymerases and uses thereof
US12247230B2 (en) 2015-05-12 2025-03-11 Dna Polymerase Technology, Inc. Mutant polymerases and uses thereof

Also Published As

Publication number Publication date
WO2008034110A9 (en) 2013-09-12
AU2007296180A1 (en) 2008-03-20
WO2008034110A2 (en) 2008-03-20
US20150368624A1 (en) 2015-12-24
CA2664043A1 (en) 2008-03-20
JP5457184B2 (ja) 2014-04-02
JP2010503413A (ja) 2010-02-04
WO2008034110A3 (en) 2008-12-24
US9796965B2 (en) 2017-10-24
JP2014054254A (ja) 2014-03-27
EP2061894A4 (en) 2010-05-05
EP2061894A2 (en) 2009-05-27

Similar Documents

Publication Publication Date Title
US9796965B2 (en) Use of Taq polymerase mutant enzymes for nucleic acid amplification in the presence of PCR inhibitors
US8470563B2 (en) Use of whole blood in PCR reactions
US9157073B1 (en) DNA polymerases
US8846312B2 (en) Compositions and methods for detecting certain flaviviruses, including members of the Japanese encephalitis virus serogroup
JPH09107997A (ja) 標的核酸の増幅方法及び増幅キット並びにｐｃｒ用組成物
KR102030244B1 (ko) 뎅기 바이러스 검출용 올리고뉴클레오티드 세트 및 이의 용도
US10100292B2 (en) Mutant endonuclease V enzymes and applications thereof
US11920185B2 (en) Method of inactivating microbes by citraconic anhydride
US9920358B2 (en) Helicase suppression of non-template amplification
WO2009140497A1 (en) Enzyme reagents for amplification of polynucleotides in the presence of inhibitors
JP7180944B1 (ja) 改変型ｄｎａポリメラーゼ
WO2021262013A1 (en) Bst-nec dna fusion polymerase for use in isothermal replication of specific sars cov-2 virus sequences
JP2023552693A (ja) 標的遺伝子変異及びウイルスゲノムの検出システム並びにその製造及び使用の方法
US20250197923A1 (en) DNA Polymerases and Related Methods
JP2024095136A (ja) 新型コロナウィルス変異オミクロン株の判別方法、および、検出キット
Hedman DNA analysis of PCR-inhibitory forensic samples
JP2003093055A (ja) Ｄｎａポリメラーゼの調製方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: DNA POLYMERASE TECHNOLOGY, INC., MISSOURI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KERMEKCHIEV, MILKO B.;KIRILOVA, LYUBKA;ZHANG, ZHIAN;SIGNING DATES FROM 20090827 TO 20090902;REEL/FRAME:023215/0640

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:DNA POLYMERASE TECHNOLOGY, INC.;REEL/FRAME:027468/0614

Effective date: 20111229

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION